News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
166,913 Results
Type
Article (6687)
Company Profile (130)
Press Release (160096)
Section
Business (53819)
Career Advice (349)
Deals (9757)
Drug Delivery (30)
Drug Development (31937)
Employer Resources (67)
FDA (2718)
Job Trends (4130)
News (96483)
Policy (6742)
Tag
Academia (254)
Alliances (12215)
Alzheimer's disease (359)
Approvals (2716)
Artificial intelligence (44)
Bankruptcy (60)
Best Places to Work (3210)
Biotechnology (84)
Breast cancer (38)
Cancer (417)
Career advice (299)
Cell therapy (88)
Clinical research (26645)
Collaboration (158)
Compensation (143)
COVID-19 (645)
C-suite (48)
Data (513)
Diabetes (44)
Diagnostics (584)
Earnings (22607)
Employer resources (59)
Events (33189)
Executive appointments (173)
FDA (2907)
Funding (118)
Gene therapy (44)
GLP-1 (213)
Government (704)
Healthcare (2277)
Infectious disease (666)
Inflammatory bowel disease (40)
Interviews (56)
IPO (5730)
Job creations (1022)
Job search strategy (258)
Layoffs (116)
Legal (900)
Lung cancer (68)
Manufacturing (85)
Medical device (446)
Medtech (447)
Mergers & acquisitions (4147)
Metabolic disorders (153)
Neuroscience (464)
NextGen Class of 2024 (972)
Non-profit (236)
Northern California (696)
Obesity (77)
Opinion (73)
People (16955)
Pharmaceutical (45)
Phase I (8054)
Phase II (12278)
Phase III (8962)
Pipeline (222)
Podcasts (35)
Policy (41)
Postmarket research (511)
Preclinical (3012)
Radiopharmaceuticals (107)
Rare diseases (66)
Real estate (1198)
Regulatory (5540)
Research institute (280)
Resumes & cover letters (40)
Southern California (568)
Startups (955)
United States (5372)
Vaccines (126)
Weight loss (43)
Date
Last 7 days (212)
Last 30 days (759)
Last 365 days (12560)
2024 (12498)
2023 (14345)
2022 (16206)
2021 (17853)
2020 (15242)
2019 (10008)
2018 (7160)
2017 (8983)
2016 (7360)
2015 (9317)
2014 (7062)
2013 (5085)
2012 (4915)
2011 (4844)
2010 (4810)
Location
Africa (164)
Asia (13302)
Australia (1444)
California (1471)
Canada (388)
China (185)
Colorado (53)
Connecticut (62)
Delaware (45)
Europe (24100)
Florida (159)
Georgia (44)
Illinois (68)
Indiana (52)
Japan (36)
Kansas (46)
Maryland (174)
Massachusetts (1189)
Minnesota (56)
New Jersey (526)
New York (508)
North Carolina (283)
Northern California (696)
Ohio (51)
Pennsylvania (278)
South America (209)
Southern California (568)
Texas (148)
Washington State (107)
166,913 Results for "aytu biopharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Aytu BioPharma, Inc. today announced the successful refinancing of its existing term loan and extension of its revolving credit facility on more favorable terms to the Company.
June 18, 2024
·
6 min read
Press Releases
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
November 14, 2024
·
19 min read
Press Releases
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
October 15, 2024
·
1 min read
Business
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024.
May 8, 2024
·
1 min read
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Aytu BioPharma, Inc. today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference.
April 3, 2024
·
1 min read
Press Releases
Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024
November 7, 2024
·
1 min read
BioMidwest
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Aytu BioPharma, Inc. announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
May 23, 2024
·
1 min read
Business
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter.
February 14, 2024
·
14 min read
Press Releases
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
September 27, 2024
·
21 min read
Business
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023, after the market close on Wednesday, February 14, 2024.
February 7, 2024
·
2 min read
1 of 16,692
Next
